GlassScriptPhysician profile
Inder P Singh
NPI 1386690139
$19,899.55
in general payments reported to CMS, 2019-2025
20 companies · $7,736 in 2025
The $7,736 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,471 · 2020: $2,479 · 2021: $996 · 2022: $2,298 · 2023: $576 · 2024: $344 · 2025: $7,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,640 · Food and Beverage: $1,616 · Consulting Fee: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,639.83 |
| Food and Beverage | $1,615.70 |
| Consulting Fee | $1,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $6,321.75 | 2022-2025 | Vyzulta |
| Kala Pharmaceuticals, INC. | $5,208.39 | 2019-2021 | |
| Abbvie INC. | $2,024.87 | 2022-2024 | |
| Nordic Pharma, INC. | $1,400.00 | 2025 | Lacrifill |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,016.89 | 2019-2025 | Jardiance |
| Sun Pharmaceutical Industries INC. | $975.01 | 2019-2023 | Cequa, Xelpros, Bromsite |
| Janssen Pharmaceuticals, INC | $852.91 | 2019 | |
| Amgen INC. | $558.39 | 2020-2025 | Repatha, Repatha |
| Novo Nordisk INC | $327.23 | 2019-2023 | Rybelsus, Tresiba, Ozempic |
| Ivantis, INC | $289.84 | 2019 | |
| Lilly USA, LLC | $276.76 | 2019-2023 | Jardiance |
| Microvention, INC. | $148.89 | 2021 | |
| Akcea Therapeutics, INC. | $124.91 | 2020 | |
| Biotissue Holdings INC. | $110.18 | 2024 | |
| Eyevance Pharmaceuticals LLC | $106.00 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $55.57 | 2021-2022 | |
| Oyster Point Pharma, INC. | $40.63 | 2022 | |
| Esperion Therapeutics, INC. | $22.95 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.33 | 2020 | |
| Merck Sharp & Dohme LLC | $16.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.